|
Q-844
|
Friday, February 6, 2026 |
With regard to Health Canada and the Public Health Agency of Canada, and any policies, programs, agreements, or initiatives related to organ and tissue donation, including where medical assistance in dying is involved: (a) is the government planning to request or recommend that the provinces and territories make changes or amendments to their Human Organ and Tissue Donation Acts (or equivalent legislation), including, but not limited to, (i) introducing or expanding deemed consent including opt-out systems, (ii) changing consent requirements or procedures for organ or tissue donation in the context of medical assistance in dying, (iii) modifying any provisions relating to next-of-kin consent, substituted decision-making or informed consent; (b) if the answer to (a) is affirmative, for each province or territory, what changes have been requested or proposed, and on what dates, and through what mechanism (letters, working groups, federal- provincial-territorial tables); (c) does the medical assistance in dying assessment or consent process, including any federal medical assistance in dying guidance or model forms, include an explicit opt-in or opt-out provision regarding organ or tissue donation; (d) are there any current or planned changes to the forms, guidance, or processes referenced in (c) that would alter how consent for organ or tissue donation is sought from medical assistance in dying patients (for example, making donation discussion mandatory, changing timing, or changing who raises the topic); (e) at what point in the medical assistance in dying process (before final consent, after final consent, during eligibility assessment) are patients first informed about the possibility of organ or tissue donation, and by whom; (f) what safeguards, if any, are in place to ensure that (i) medical assistance in dying eligibility and decision-making are fully independent from any organ or tissue donation considerations, (ii) medical assistance in dying patients are not unduly influenced, coerced or incentivized to consent to donation, (iii) health care providers and organ donation organizations avoid conflicts of interest; (g) since January 1, 2020, broken down by calendar year and by province or territory, what is the (i) number of medical assistance in dying patients referred for organ or tissue donation, (ii) number of referred medical assistance in dying patients assessed as eligible for organ or tissue donation, (iii) number of eligible medical assistance in dying patients who were approached regarding organ or tissue donation, (iv) number of medical assistance in dying patients who provided consent to organ or tissue donation, (v) number of organs recovered and utilized for transplantation from medical assistance in dying donors, by organ type (kidney, liver, lung, heart, pancreas, etc.), (vi) number of tissues recovered and utilized from medical assistance in dying donors, by tissue type (corneas, heart valves, bone, skin, etc.), (vii) average number of organs transplanted per medical assistance in dying donor, by year, and, where data is not available or not collected, for which variables, years, or jurisdictions is this the case and why; (h) starting in 2020, broken down by calendar year and by organ and tissue type, (i) how many Canadian organs and tissues were exported outside Canada for transplantation, research, or any other purpose, (ii) for each exported organ or tissue type, what was the destination country and intended use category (therapeutic transplant, research, education, commercial use), (iii) how many of these exported organs or tissues originated from medical assistance in dying donors, if known; (i) for the exported organ and tissue donations identified in (h), (i) what fees, charges, or other financial or in-kind consideration were associated with each organ or tissue type (cost-recovery, procurement fees, transport, logistics charges, processing fees), (ii) for each fee or charge, who or what entity received the payment, (iii) does the federal government have any policies, agreements or guidance regarding cost-recovery, commercialization or prohibition of profit in relation to organ and tissue export, including those from medical assistance in dying donors; (j) what policies, guidelines or ethical frameworks does Health Canada or the Public Health Agency of Canada rely on to ensure that organ and tissue donation practices, including those involving medical assistance in dying patients, comply with the Canadian Charter of Rights and Freedoms, international human rights obligations, and the principle of free and informed consent; (k) since 2020, have there been any internal reviews, audits, complaints or investigations (including by ethics bodies, ombudspersons or human rights commissions) related to (i) organ and tissue donation in the context of medical assistance in dying, (ii) the export of Canadian organs and tissues; (l) if the answer to (k) is affirmative, what are the details, including the dates, the bodies involved, the nature of the concerns and any findings or corrective actions taken; and (m) are there any federal agreements, memoranda of understanding or funding conditions with provincial and territorial organ donation organizations or transplant programs that reference medical assistance in dying, organ or tissue donation from medical assistance in dying patients or export of organs and tissues, and, if so, what are the details and the dates? |
Answered |
Wednesday, March 25, 2026 |
|
Q-425
|
Tuesday, October 7, 2025 |
With regard to the government's involvement with Mark Wiseman, of
the Century Initiative and Lazard, and to meetings attended by the Prime Minister or other ministers, where Mark Wiseman was in attendance, since March 14, 2025: (a) what are the details
of all such meetings, including the (i) date, (ii) location, (iii) names and titles of the attendees, (iv)
purpose of the meeting; (b) is Mark Wiseman receiving a remuneration for his role on the government's
Canada-U.S. relations advisory council, and, if so, how much; (c) what are the details of all
expenditures the government has paid related to expenses incurred by Mark Wiseman, including, for
each the date, type and amount; and (d) what is the Prime Minister's position on Wiseman's claim,
in relation to immigration, that "a lot of the screening and other stuff that we do frankly is just
bureaucracy, is a waste of time"? |
Answered |
Monday, November 24, 2025 |
|
Q-109
|
Wednesday, June 4, 2025 |
With regard to the distribution of fuel charge proceeds to small and medium-sized businesses, through the Canada Carbon Rebate for Small Businesses, as authorized under section 165 of the Greenhouse Gas Pollution Pricing Act and section 127.421 of the Income Tax Act: (a) what is the total amount distributed to small and medium-sized businesses under the Canada Carbon Rebate since the program’s inception, broken down by (i) province or territory, (ii) year, (iii) industry sector (e.g., manufacturing, retail, hospitality), (iv) type of payment or credit provided; (b) for each fiscal year since the inception of the program, what (i) amount was allocated by the government to be returned to small and medium-sized businesses through the Canada Carbon Rebate, (ii) amount was ultimately distributed, (iii) is the explanation for any discrepancies between the amounts allocated and the amounts distributed; and (c) what explains the $108 million difference between the $3.3 billion intended to be returned to businesses based on net fuel charge proceeds for the 2019–20 to 2023–24 years, as reported in the 2024 Public Accounts (Volume I, page 16) and the $3.192 billion attributed to the Canada Revenue Agency for this same purpose, as reported in the Main Estimates? |
Answered |
Monday, September 15, 2025 |
